Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 7/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.38 |
| ▸ | ITGAL | P20701 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344446 | 1.00 | GPR183 (0.43) | GPR183PRMT5WDR77PYGLNPC1 | |
| SCHEMBL2904321 | 0.92 | GPR183 (0.45) | GPR183PYGLNPC1RAB9ATDP1 | |
| SCHEMBL2904323 | 0.92 | GPR183 (0.45) | GPR183PYGLNPC1RAB9ATDP1 | |
| SCHEMBL2904318 | 0.92 | GPR183 (0.45) | GPR183PYGLNPC1RAB9ATDP1 | |
| SCHEMBL1343320 | 0.92 | GPR183 (0.50) | GPR183PRMT5WDR77PYGLNPC1 | |
| SCHEMBL1343318 | 0.92 | GPR183 (0.50) | GPR183PRMT5WDR77PYGLNPC1 | |
| SCHEMBL1344367 | 0.88 | PRMT5 (0.46) | GPR183PRMT5WDR77 | |
| SCHEMBL1344365 | 0.88 | PRMT5 (0.46) | GPR183PRMT5WDR77 | |
| SCHEMBL2902254 | 0.83 | GPR183 (0.52) | GPR183PYGLNPC1RAB9ATDP1 | |
| SCHEMBL2902256 | 0.83 | GPR183 (0.52) | GPR183PYGLNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009010429-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | GPR183 44/4885PRMT5 823/4885WDR77 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.